Dendritic cell vaccines
Bigalke I., Eckl J., Solum G., Hønnåshagen K., Skoge L., Fløisand Y., Josefsen D., Sæbøe-Larssen S., Geiger C., Schendel D., Kvalheim G. 2018. Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use
Download PDF
Subklewe M., Geiger C., Lichtenegger F., Javorovic M., Kvalheim G., Schendel D.J., Bigalke I. 2014. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunology. 10.1007/s00262-014-1600-5
Download PDF
Lichtenegger, F. S., Mueller, K., Otte, B., Beck, B., Hiddemann, W., Schendel, D. J. and M. Subklewe. 2012. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One. 7(9): e44266.
Further information
Spranger, S., Frankenberger, B. and D. J. Schendel. 2012. NOD/scid IL-2Rgnull mice: a pre-clinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J Transl. Med. 10(1): 30. [Epub ahead of print]
Further information
Frankenberger, B. and D.J. Schendel. 2012. Third generation dendritic cell vaccines for tumor immunotherapy. Eur. J. Cell Biol. 91(1): 53-58 [Epub 2011 Mar 25]
Further information
Beck, B., Dörfel, D., Lichtenegger, F.S., Geiger, C., Lindner, L., Merk, M., Schendel, D.J., and M. Subklewe. 2011. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J. Transl. Med. 9:151 [Epub. Sep. 13]
Further information
Bürdek M., Spranger S., Wilde S., Frankenberger B., Schendel D.J. and C. Geiger. 2010 Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation. J. Transl. Med. 8:90.
Further information
Spranger, S., Javorovic, M., Bürdek, M., Wilde, S., Mosetter, B., Tippmer, S., Bigalke, I., Geiger, C., Schendel, D.J. and B. Frankenberger. 2010. Generation of T helper-1 polarizing dendritic cells using the Toll-like receptor 7/8 agonist CL075. J. Immunol. 185(1): 738-747.
Further information
Javorovic, M., Wilde, S., Zobywalski, A., Noessner, E., Lennerz, V., Wölfel, T., and D.J. Schendel. 2008. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J. Immunother 31(1): 52-62.
Further information
Zobywalski, A., Javorovic, M., Frankenberger, B., Pohla, H., Kremmer, E., Bigalke, I. and D.J. Schendel. 2007. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl Med. 5:18 (highly accessed).
Further information
T cell receptor (TCR)-modified T cells for adoptive T cell therapy
Jaravine, V., Raffegerst, S., Schendel, DJ., Frishman, D. Assessment of cancer and virus antigens for cross-reactivity in human tissues Bioinformatics 2017 Jan 1;33(1):104-111. doi: 10.1093/bioinformatics/btw567.
Further Information
Schlenker, R., Olguín-Contreras, L., Leisegang, M., Schnappinger, J., Disovic, A., Rühland, S., Nelson, P., Leonhardt, H., Harz, H., Wilde, S., Schendel, D. Uckert, W., Willimsky, G. and Noessner, E. Cancer Research, 2017. Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy
Further information
Haase, K., Raffegerst, S., Schendel, D., Frishman, D. Expitope: a web server for epitope expression. Bioinformatics. 2015 Jun 1;31(11):1854-6. doi: 10.1093/bioinformatics/btv068.
Further information
Obenaus, M., Leitão, C., Leisegang, M., Chen, X., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D.J. and Blankenstein, T. 2015. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nature Biotechnology 33, 402–407 (2015).
Further information
Schendel, D.J. and P.D. Greenberg. 2014. The ABC’s of T cell receptor gene therapy. In: Cancer Immunotherapy Meets Oncology (Britten, C.M., Kreiter, S., Diken, M., Rammensee, H.-G., Eds). Pp. 117-126. Springer International Publishing, Switzerland, Heidelberg, Dordrecht, London, New York, 25.05.2014.
Further information
Pinto, S., Sommermeyer, D., Michel, C., Wilde, S., Schendel, D, Uckert, W., Blankenstein T., Kyewski, B. 2014. Mis-initiation of MART-1 transcription in the thymus and biased TCR usage can explain the high frequency of peripheral MART-1 specific T cells. Eur J Immunol. 2014 May 20 [Epub ahead of print].
Further information
Schendel, D.J. and Frankenberger, B. 2013. Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity. Oncoimmunology. 2013 Jan 1; 2(1):e22410.
Further information
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gross, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., Phan, G., Hughes, M. S., Kammula, U. S., Miller, A., Hessman, C., Stewart, A., Restifo, R., Quezado, M. M. (+ other members of Pathology staff), Nath, A., Wang, D., Bielekova, B., Wuest, S., Nirmala, A., (+ others, NIMH deep sequencing group), Schendel, D. J., Wilde, S., Mosetter, B., Laurencot, C. and Rosenberg, S. A. 2013. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 36(2):133-151.
Further information
Wilde, S. and D.J., Schendel. 2012. High-quality and high-avidity T cell clones specific for tumor-targeted antigens and how to find them. Oncoimmunology. 1(9):1643-1644.
Further information
Wilde, S., Sommermeyer, D., Leisegang, M., Frankenberger, B., Mosetter, B., Uckert, W. and D. J. Schendel. 2012. Human antitumor CD8+ T cells producing Th1-polycytokines show superior antigen sensitivity and tumor recognition. J Immunol. 189(2): 598-605.
Further information
Wilde, S., Geiger, C., Milosevic, S., Mosetter, B., Eichenlaub, S. and D.J. Schendel. 2012. Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure. Oncoimmunology. 1(2): 129-140.
Further information
Spranger, S., Jeremias, I., Wilde, S., Leisegang, M., Stärck, L., Mosetter, B., Uckert, W., Heemskerk, M., *Schendel, D. J. and B. *Frankenberger. 2012. T cell receptor-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. (* equal senior authors) Blood. 119(15): 3440-3449. [Epub ahead of print].
Further information
Leisegang M., Wilde S., Spranger S., Milosevic S., Frankenberger B., Uckert W. and D.J. Schendel. 2010. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J. Clin. Invest. 120 (11): 3869-3877.
Further information
Wilde, S., Sommermeyer, D., Frankenberger, B., Schiemann, M., Milosevic, S., Spranger, S., Pohla, H., Uckert, W., Busch, D.H. and D.J. Schendel. 2009. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior anti-tumor activity and higher TCR functional avidity. Blood 114(10): 2131-2139.
Further information
Becker, C., Pohla, H., Frankenberger, B., Schüler, T., Assenmacher, M., Schendel, D.J. and Blankenstein, T. 2001. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat Med.; 7 (10):1159–1162.
Further information